Fig. 4From: Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer PIK3CA analyses. a PIK3CA status and relationship to outcome per treatment group. b Analysis of PIK3CA mutations by estrogen receptor (ER) status and relationship to outcome. Mut mutant, pCR pathologic complete response, PIK3CA gene encoding phosphoinositide 3-kinase, catalytic subunit, WT wild-typeBack to article page